GlassScriptPhysician profile
Han N Lee
NPI 1558457143
$10,608.39
in general payments reported to CMS, 2019-2025
41 companies · $2,634 in 2025
The $2,634 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $682 · 2021: $858 · 2022: $1,367 · 2023: $1,829 · 2024: $2,025 · 2025: $2,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,445 · Education: $42.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,445.11 |
| Education | $42.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,619.87 | 2019-2025 | |
| Genzyme Corporation | $1,578.02 | 2021-2025 | |
| Galderma Laboratories, L.P. | $864.82 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $846.73 | 2019-2025 | |
| Allergan, INC. | $648.50 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $582.52 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $372.00 | 2019-2025 | Anzupgo, Adbry |
| Incyte Corporation | $315.21 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $310.45 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $274.57 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $262.37 | 2019-2025 | |
| Revance Therapeutics, INC. | $256.20 | 2024 | Daxxify |
| Janssen Biotech, INC. | $205.53 | 2020-2023 | Tremfya |
| Dermavant Sciences, INC. | $180.86 | 2022-2024 | Vtama |
| Ucb, INC. | $156.34 | 2021-2025 | Bimzelx |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Han Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.